Samuel D Riccitelli
CIK 1414839 · Interim President and CEO · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GXDX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WARSAW, IN 46582
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KIDS | Director | 31,859 | $32.52 | $1.04M | $0 | 9 | 2026-06-10 |
| BIOCEPT INC (BIOC) Delisted | Interim President and CEO | — | $0.43 | — | $0 | 3 | 2022-03-02 |
| PRPO | Director | — | $18.70 | — | $0 | 3 | 2019-03-20 |
| Viridian Therapeutics, Inc.\DE (SGNL) Delisted | President & CEO | 38,091 | — | — | $11.1K | 7 | 2016-11-02 |
| GENOPTIX INC (GXDX) Delisted | Ex VP and COO | 49 | — | — | -$4.01M | 27 | 2011-03-07 |
Recent Filings · Page 3 of 5
49 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-23 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Mixed | +78,216 | -$69.5K | EDGAR |
| 2015-04-10 | Viridian Therapeutics, Inc.\DE (SGNL) Delisted | Mixed | +252,914 | -$249.3K | EDGAR |
| 2011-03-07 | GENOPTIX INC (GXDX) Delisted | Disp (D) | −8,950 | -$223.8K | EDGAR |
| 2011-03-01 | GENOPTIX INC (GXDX) Delisted | Mixed | −28,878 | -$3.68M | EDGAR |
| 2011-01-04 | GENOPTIX INC (GXDX) Delisted | Tax (F) | −2,064 | -$39.9K | EDGAR |
| 2010-12-17 | GENOPTIX INC (GXDX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2010-10-05 | GENOPTIX INC (GXDX) Delisted | Tax (F) | −919 | -$13.4K | EDGAR |
| 2010-07-06 | GENOPTIX INC (GXDX) Delisted | Tax (F) | −919 | -$15.8K | EDGAR |
| 2010-04-13 | GENOPTIX INC (GXDX) Delisted | Mixed | — | -$352.7K | EDGAR |
| 2010-04-05 | GENOPTIX INC (GXDX) Delisted | Tax (F) | −919 | -$32.9K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).